1. Royal College of Physicians of Edinburgh. Hepatitis
C: a report produced by a working party of the Royal
College of Physicians of Edinburgh. Edinburgh: Royal
College of Physicians of Edinburgh; 1995.
2. Chief Medical Officer. Hepatitis C (HCV) and blood
transfusion. Edinburgh: Scottish Home Office and
Health Department; 1995.
3. Thomas HC, Weatherall DT, Ledingham J,
Warrell DA. Clinical features of viral hepatitis.
Oxford textbook of medicine. 3rd ed. Oxford: Oxford
University Press; 1996. pp. 2061–9.
4. Poynard T, Bedossa P, Opolon, P. Natural history
of liver fibrosis progression in patients with
chronic hepatitis C. Lancet 1997;349;825–32.
5. Di Bisceglie AM. Hepatitis C. Lancet 1998;
351:351–5.
6. Seeff LB. Natural history of chronic hepatitis C.
Hepatology 2002;36:S35–46.
7. Ortiz V, Berenguer M, Rayon JM, Carrasco D,
Berenguer J. Contribution of obesity to hepatitis
C-related fibrosis progression. Am J Gastroenterol
2002;97:2408–14.
8. Poynard T, Ratziu V, Charlotte F, Goodman Z,
McHutchison J, Albrecht J. Rates and risk factors
of liver fibrosis progression in patients with
chronic hepatitis C. J Hepatol 2001;34:730–9.
9. McQuillan GM, Alter MJ, Moyer LA, Lambert SB,
Margolis HS. A population based serologic study
of hepatitis C virus infection in the United States.
In: Rizzetto M, Purcell R, Gerin J, Verne G,
editors. Viral hepatitis and liver disease. Turin:
Edizioni Minerva Medica; 1997. pp. 267–70.
10. Ramsay ME, Balogun MA, Collins M, Balraj V.
Laboratory surveillance of hepatitis C virus
infection in England and Wales: 1992 to 1996.
Commun Dis Public Health 1998;1:89–94.
11. Mohsen AH, Trent HCV Study Group. The
epidemiology of hepatitis C in a UK health
regional population of 5.12 million. Gut 2001;
48:707–13.
12. Public Health Laboratory Service. Unlinked
Anonymous HIV Prevalence Monitoring Programme –
England and Wales. London: Department of
Health; 1996.
13. Harris KA, Gilham C, Mortimer PP, Teo CG.
The most prevalent hepatitis C virus genotypes in
England and Wales are 3a and 1a. J Med Virol
1999;58:127–31.
14. Dusheiko GM, Roberts JA. Treatment of chronic
type B and C hepatitis with interferon alfa: an
economic appraisal. Hepatology 1995;22:1863–73.
15. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H,
Takeda T, Nakajima S, et al. Randomised trial of
effects of interferon-alpha on incidence of
hepatocellular carcinoma in chronic active hepatitis
C with cirrhosis. Lancet 1995; 346:1051–5.
16. Marcellin P, Boyer N, Gervais A, Martinot M,
Pouteau M, Castelnau C, et al. Long-term
histologic improvement and loss of detectable
intrahepatic HCV RNA in patients with chronic
hepatitis C and sustained response to interferonalpha
therapy. Ann Intern Med 1997;127:875–81.
17. Bayliss MS. Methods in outcomes research in
hepatology: definitions and domains of quality of
life. Hepatology 1999;29:3–6S.
18. Conry CC, VanRaden M, Gibble J, Melpolder J,
Shakil AO, Viladomiu L, et al. Routes of infection,
viremia, and liver disease in blood donors found
to have hepatitis C virus infection. N Engl J Med
1996;334:1691–6.
19. Poynard T, Cacoub P, Ratziu V, Myers RP,
Dezailles MH, Mercadier A, et al. Fatigue in
patients with chronic hepatitis C. J Viral Hepat
2002;9:295–303.
20. Forton DM, Thomas HC, Murphy CA, Allsop JM,
Foster GR, Main J, et al. Hepatitis C and cognitive
impairment in a cohort of patients with mild liver
disease. Hepatology 2002;35:433–9.
21. Forton DM, Taylor-Robinson SD, Thomas HC.
Reduced quality of life in hepatitis C – is it all in
the head? J Hepatol 2002;36:435–8.
22. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36
health survey: manual and interpretation guide.
Boston, MA: Health Institute, New England
Medical Center; 1993.
23. Bonkovsky HL, Woolley JM. Reduction of healthrelated
quality of life in chronic hepatitis C and
improvement with interferon therapy.The
Consensus Interferon Study Group. Hepatology
1999;29:264–70.
24. Carithers RL, Sugano D, Bayliss M. Health
assessment for chronic HCV infection: results of
quality of life. Dig Dis Sci 1996;41:75–80S.
25. Foster GR, Goldin RD, Thomas HC. Chronic
hepatitis C virus infection causes a significant
reduction in quality of life in the absence of
cirrhosis. Hepatology 1998;27:209–12.
26. Fontana RJ, Hussain KB, Schwartz SM, Moyer CA,
Su GL, Lok AS. Emotional distress in chronic
hepatitis C patients not receiving antiviral therapy.
J Hepatol 2002;36:401–7.
27. Hunt CM, Dominitz JA, Bute BP, Waters B,
Blasi U, Williams DM. Effect of interferon-alpha
treatment of chronic hepatitis C on health-related
quality of life. Dig Dis Sci 1997;42:2482–6.
28. Ware JE, Bayliss MS, Mannocchia M, Davis GL,
Bassaris H, Batey R, et al. Health-related quality of
life in chronic hepatitis C: impact of disease and
treatment response. Hepatology 1999;30:550–5.
29. Neary MP, Cort S, Bayliss MS, Ware JE. Sustained
virologic response is associated with improved
health-related quality of life in relapsed chronic
hepatitis C patients. Semin Liver Dis 1999;
19:77–86.
30. Myers RP, Regimbeau C, Thevenot T, Leroy V,
Mathurin P, Opolon P, et al. Interferon for
interferon naive patients with chronic hepatitis C
(Cochrane Review). Cochrane Database Syst Rev
2002;CD000370.
31. Poynard T, McHutchison J, Goodman Z, Ling MH,
Albrecht J. Is an ‘à la carte’ combination interferon
alfa-2b plus ribavirin regimen possible for the first
line treatment in patients with chronic hepatitis C?
The ALGOVIRC Project Group. Hepatology
2000;31:211–18.
32. Davis GL, Esteban MR, Rustgi V, Hoefs J,
Gordon SC, Trepo C, et al. Interferon alfa-2b alone
or in combination with ribavirin for the treatment
of relapse of chronic hepatitis C. International
Hepatitis Interventional Therapy Group. N Engl J
Med 1998;339:1493–9.
33. Foster GR, Chapman R. Combination treatment
for hepatitis C is not being given. BMJ 2000;
321:899.
34. Shepherd J, Waugh N, Hewitson P. Combination
therapy (interferon alfa and ribavirin) in the
treatment of chronic hepatitis C: a rapid and
systematic review. Health Technol Assess 2000;4(33).
35. National Institute for Clinical Excellence. Guidance
on the use of ribavirin and interferon alpha for hepatitis
C. London: National Institute for Clinical
Excellence; 2000.
36. Booth J, O’Grady J, Neuberger J, on behalf of the
Royal College of Physicians of London and the
British Society of Gastroenterology. Clinical
guidelines on the management of hepatitis C.
Gut 2001;49:1–21.
37. Cramp M, Rosenburg W. Guidance on the treatment
of hepatitis C incorporating the use of pegylated
interferons. London: British Society for
Gastroenterology; 2003.
38. Davis GL. Treatment of chronic hepatitis C. BMJ
2001;323:1141–2.
39. British Medical Association. British National
Formulary. London: Royal Pharmaceutical Society
of Great Britain; 2002.
40. Reddy KR, Wright TL, Pockros PJ, Shiffman M,
Everson G, Reindollar R, et al. Efficacy and safety
of pegylated (40-kd) interferon -2a compared
with interferon -2a in noncirrhotic patients with
chronic hepatitis C. Hepatology 2001;33:433–8.
41. Manns MP, McHutchison JG, Gordon SC, Rustgi
VK, Shiffman M, Reindollar R, et al. Peginterferon
alfa-2b plus ribavirin compared with interferon
alfa-2b plus ribavirin for initial treatment of
chronic hepatitis C: a randomised trial. Lancet
2001;358:958–65.
42. Scottish Medicines Consortium. The Scottish
Medicines Consortium advises on pegylated
interferon alpha-2b (ViraferonPeg).
http://www.htbs.co.uk/smc/press/index.asp?did=697
(Accessed 6 May 2003.)
43. National Institutes of Health Consensus
Development Conference Statement: Management
of Hepatitis C. 10–12 June 2002. Hepatology
2003;36:S3–20.
44. National Institutes of Health. National Institutes
of Health Consensus Development Conference
Statement Management of Hepatitis C. 10–12
June 2002. http://consensus.nih.gov/cons/116/
091202116cdc_statement.htm (Accessed 18
November 2002).
45. Cammà C, Bruno S, Schepis F, Lo IO, Andreone P,
Gramenzi AG, et al. Retreatment with interferon
plus ribavirin of chronic hepatitis C nonresponders
to interferon monotherapy: a metaanalysis
of individual patient data. Gut
2002;51:864–9.
46. Myers R P, Poynard T. Interferon for interferon
nonresponding and relapsing patients with
chronic hepatitis C (Cochrane Review). Cochrane
Database Syst Rev 2002(4).
47. Verbaan HP, Widell HE, Bondeson TL,
Lindgren SC. High sustained response rate in
patients with histologically mild (low grade and
stage) chronic hepatitis C infection. A randomized,
double blind, placebo controlled trial of interferon
alpha-2b with and without ribavirin. Eur J
Gastroenterol Hepatol 2002;14:627–33.
48. Wong VS, Hughes V, Trull A, Wight DG, Petrik J,
Alexander GJ. Serum hyaluronic acid is a useful
marker of liver fibrosis in chronic hepatitis C virus
infection. J Viral Hepat 1998;5:187–92.
49. Gilmore I T, Burroughs A, Murray-Lyon IM,
Williams R, Jenkins D, and Hopkins A.
Indications, methods, and outcomes of
precutaneous liver biopsy in England and Wales:
an audit by the British Society of Gastroenterology
and Royal College of Physicians London.
Gut 1995;36:437–41.
50. Fried MW, Shiffman ML, Reddy KR, Smith C,
Marinos G, Goncales FL, et al. Peginterferon alfa-
2a plus ribavirin for chronic hepatitis C virus
infection. N Engl J Med 2002;347:975–82.
51. Jaeckel E, Cornberg M, Wedemeyer H,
Santantonio T, Mayer J, Zankel M, et al. Treatment
of acute hepatitis C with interferon alfa-2b. N Engl
J Med 2001;345:1452–7.
52. Lindsay KL, Trepo C, Heintges T, Shiffman ML,
Gordon SC, Hoefs JC, et al. A randomized,
double-blind trial comparing pegylated interferon
alfa-2b to interferon alfa-2b as initial treatment for
chronic hepatitis C. Hepatology 2001;34:395–403.
53. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ,
Lai MY, Gane E, et al. Peginterferon alfa-2a in
patients with chronic hepatitis C. N Engl J Med
2000;343:1666–72.
54. Heathcote EJ, Shiffman ML, Cooksley WGE,
Dusheiko GM, Lee SS, Balart L, et al.
Peginterferon alfa-2a in patients with chronic
hepatitis C and cirrhosis. N Engl J Med
2000;343:1673–80.
55. Balogun MA, Ramsay ME, Parry JV, Donovan L,
Andrews NJ, Newham JA, et al. The prevalence
and genetic diversity of hepatitis C infection in
antenatal clinic attenders in two regions of
England. Epidemiol Infect 2000;125:705–12.
56. Davis GL. Monitoring of viral levels during
therapy of hepatitis C. Hepatology 2002;
36:S145–51.
57. Poynard T, Marcellin P, Lee SS, Niederau C,
Minuk GS, Ideo G, et al. Randomised trial of
interferon alpha2b plus ribavirin for 48 weeks or
for 24 weeks versus interferon alpha2b plus
placebo for 48 weeks for treatment of chronic
infection with hepatitis C virus. International
Hepatitis Interventional Therapy Group (IHIT).
Lancet 1998;352:1426–32.
58. McHutchison J, Manns M, Harvey J, Albrecht JK.
Adherence to therapy enhances sustained response
in chronic hepatitis C patients receiving peginterferon
alfa-2b plus ribavirin [abstract].
J Hepatol 2001;34:2–3.
59. McHutchison JG, Gordon SC, Schiff ER, Shiffman
ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b
alone or in combination with ribavirin as initial
treatment for chronic hepatitis C. Hepatitis
Interventional Therapy Group. N Engl J Med
1998;339:1485–92.
60. Hadziyannis SJ, Cheinquer H, Morgan T,
Diago M, Jensen DM, Sette H, et al. Peginterferon
alfa-2a (40 Kd) (Pegasys) in combination with
ribavirin (RBV): efficacy and safety results from a
phase III, randomized, double-blind, multicentre
study examining effect of duration of treatment
and RBV dose. J Hepatol 2002;36(1):3.
61. Shobokshi O, Skakni L. Peg-IFN alfa-2a (40kDa)
as a monotherapy or in combination with ribavirin
significantly improve end of treatment response
rate in HCV genotype 4 chronic active hepatitis
(CAH) patients [abstract]. 53rd Annual Meeting on
the Liver, 1–5 November 2002, Boston, MA, USA.
Hepatology 2002;36:362A.
62. Shobokshi O, Serebour F, Skakni L, Tantawi A,
Dinish T, Al-Quaiz M. Efficacy of pegylated (40
kDa) IFN alfa-2a (Pegasys) plus ribavirin in the
treatment of hepatitis C genotype 4 chronic active
patients in Saudi Arabia [abstract]. J Hepatol
2002;36:129.
63. Esmat GM, Abdel-Aziz FK, Abdel-Hamid MS,
Ismail SA, Zalata KR, Mikhail NN.Treatment with
PEG-interferon alfa-2b (PEG-IFN) plus ribavirin
compared to interferon alfa-2b (IFN alfa-2b) plus
ribavirin on subjects with chronic hepatitis C
infected with HCV genotype 4 [abstract]. 53rd
Annual Meeting on the Liver, 1–5 November
2002, Boston, MA, USA. Hepatology 2002;36:364A.
64. Pockros P, Carithers R, Desmond P, Dhumeaux D,
Fried M, Marcellin P. Evaluation of two doses of
peginterferon alfa-2a for the treatment of chronic
hepatitis C (CHC) [abstract]. 41st Interscience
Conference on Antimicrobial Agents and
Chemotherapy (ICAAC 2001) 16–19 December
2001, Chicago, IL, USA.
65. Gebo, KA, Jenckes MW, Chander G, Torbenson
MS, Ghanem KG, Herlong HF, et al. Management
of chronic hepatitis C. Evidence
Report/Technology Assessment No.60. Agency for
Healthcare Research and Quality; 2002.
www.ahrq.gov
66. Chander G, Sulkowski MS, Jenckes MW,
Torbenson MS, Herlong HF, Bass EB, et al.
Treatment of chronic hepatitis C: a systematic
review. Hepatology 2002;36:S135–44.
67. Poynard T, McHutchison J, Manns M, Trepo C,
Lindsay K, Goodman Z, et al. Impact of pegylated
interferon alfa-2b and ribavirin on liver fibrosis in
patients with chronic hepatitis C. Gastroenterology
2002;122:1303–13.
68. Myers RP, Abdo A, Poynard T. Pegylated interferon
alfa for chronic hepatitis C (Protocol for a
Cochrane Review). In The Cochrane Library (Issue
1). Oxford: Update Software; 2003.
69. Mohsen A, Easterbrook P, Taylor C, Norris S.
Hepatitis C and HIV-1 coinfection. Gut 2002;
51:601–8.
70. Perronne C, Carrat F, Banisadr F, Morand P,
Lunel F, Rosenthal E, et al. ANRS HC02-Ribavic:
a randomized controlled trial of pegylated
interferon alpha-2b plus ribavirin vs interferon
alpha-2b plus ribavirin as primary treatment of
chronic hepatitis C in HIV co-infected patient
[abstract]. Hepatology 2002;36:283A.
71. Banisadr F, Carrat F, Pol S, Rosenthal E,
Morand P, Lunel F, et al. Effects of HCV treatment
on HIV course. Preliminary results of the ANRS
HC 02-Ribavic study: a randomized, controlled
trial of pegylated interferon alpha-2B with
ribavirin vs interferon alpha-2b with ribavirin for
the tratment of chronic HCV in HIV co-infection
[abstract]. Hepatology 2002;36:585A.
72. Goelz J, Klausen G, Moll A, Schleehauf D,
Prziwara D, Cordes C, Nzimegne, GA. Efficacy
and tolerance of therapy in IFN-alpha/RBV and
pegIFN-alpha/RBV in HIV-/HCV-coinfected
IVDUs [abstract]. XIV International AIDS
Barcelona, Conference, 7 July 2002.
73. Juarez A, Esteban JI, Sauleda S, Ribera E, Ocana
I, Ruiz I, et al. Randomized trial of Intron A and
ribavirin versus Peg-Intron and ribavirin in HIV
HCV coinfected patients. Interim report on safety
data [abstract]. Hepatology 2001;34:418A.
74. Shiffman M. Retreatment of HCV non-responders
with peginterferon and ribavirin: results from the
lead in phase of the Hepatitis C Antiviral Long
Term Treatment against Cirrhosis (HALT-C) trial
[abstract]. Hepatology 2002;36:295A.
75. Jacobson IM, Russo MW, Brown RS, Lebovics E,
Min A, Esposito S, et al. Pegylated interferon alfa-
2b plus ribavirin in patients with chronic hepatitis
C: a trial in prior nonresponders to interferon
monotherapy or combination therapy and in
combination therapy relapsers. Gastroenterology
2002;122:79.
76. Shiffman ML. Retreatment of patients with chronic
hepatitis C. Hepatology 2002;36:S128–34.
77. Cheng SJ, Bonis PA, Lau J, Pham NQ, Wong JB.
Interferon and ribavirin for patients with chronic
hepatitis C who did not respond to previous
interferon therapy: a meta-analysis of controlled
and uncontrolled trials. Hepatology 2001;33:231–40.
78. Cummings KJ, Lee SM, West ES, Cid-Ruzafa J,
Fein SG, Aoki Y, et al. Interferon and ribavirin vs
interferon alone in the re-treatment of chronic
hepatitis C previously nonresponsive to interferon:
a meta-analysis of randomized trials. JAMA 2001;
285:193–9.
79. Kjaergard LL, Krogsgaard K, Gluud C. Ribavirin
with or without alpha interferon for chronic
hepatitis C. Cochrane Database Syst Rev 2002;
CD002234.
80. San Miguel R, Guillen F, Cabases JM, Buti M.
Meta-analysis: combination therapy with
interferon-alpha 2a/2b and ribavirin for patients
with chronic hepatitis C previously non-responsive
to interferon. Aliment Pharmacol Ther 2002;
16:1611–21.
81. Bonkovsky HL, Stefancyk D, McNeal K, Banner
BF, Liu Q, Zucker GM, et al. Comparative effects
of different doses of ribavirin plus interferon-alpha
2b for therapy of chronic hepatitis C: results of a
controlled, randomized trial. Dig Dis Sci
2001;46:2051–9.
82. Brillanti S, Foli M, Di Tomaso M, Gramantieri L,
Masci C, Bolondi L. Pilot study of triple antiviral
therapy for chronic hepatitis C in interferon alpha
non-responders. Ital J Gastroenterol Hepatol 1999;
31:130–4.
83. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N,
Brunt EM, Bacon BR.Combination of interferon
and ribavirin in chronic hepatitis C: retreatment of
nonresponders to interferon. Hepatology
2001;33:704–7.
84. Enriquez J, Gallego A, Torras X, Perez-Olmeda T,
Diago M, Soriano V, et al. Retreatment for 24 vs 48
weeks with interferon-alpha2b plus ribavirin of
chronic hepatitis C patients who relapsed or did
not respond to interferon alone. J Viral Hepat
2000;7:403–8.
85. Min AD, Jones JL, Esposito S, Lebovics E,
Jacobson IM, Klion FM, et al. Efficacy of high-dose
interferon in combination with ribavirin in
patients with chronic hepatitis C resistant to
interferon alone. Am J Gastroenterol 2001;
96:1143–9.
86. Puoti M, Cadeo GP, Putzolu V, Forleo MA, Barni
MC, Cristini G, et al. Pilot dose-finding trial on
interferon alpha in combination with ribavirin for
the treatment of chronic hepatitis C in patients not
responding to interferon alone. Dig Liver Dis
2001;33:163–72.
87. Saracco G, Ciancio A, Olivero A, Smedile A,
Roffi L, Croce G, et al. A randomized 4-arm
multicenter study of interferon alfa-2b plus
ribavirin in the treatment of patients with chronic
hepatitis C not responding to interferon alone.
Hepatology 2001;34:133–8.
88. Younossi ZM, Mullen KD, Zakko W, Hodnick S,
Brand E, Barnes DS, et al. A randomized, doubleblind
controlled trial of interferon alpha-2b and
ribavirin vs. interferon alpha-2b and amantadine
for treatment of chronic hepatitis C non-responder
to interferon monotherapy. J Hepatol
2001;34:128–33.
89. Fontana RJ, Walsh J, Moyer CA, Lok ASF,
Webster S, Klein S. High-dose interferon alfa-2b
and ribavirin in patients previously treated with
interferon – results of a prospective, randomized,
controlled trial. J Clin Gastroenterol 2002;
34:177–82.
90. Andreone P, Gramenzi A, Cursaro C, Sbolli G,
Fiorino S, di Giammarino L, et al. Interferon-alpha
plus ribavirin in chronic hepatitis C resistant to
previous interferon-alpha course: results of a
randomized multicenter trial. J Hepatol 1999;
30:788–93.
91. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G,
Bellomo G, Belloni G, et al. Interferon-alpha-2B
and ribavirin in combination for chronic hepatitis
C patients not responding to interferon-alpha
alone: an Italian multicenter, randomized,
controlled, clinical study. Am J Gastroenterol 1998;
93:2445–51.
92. Pol S, Couzigou P, Bourliere M, Abergel A,
Combis J, Larrey D, et al. A randomized trial of
ribavirin and interferon-alpha vs. interferon-alpha
alone in patients with chronic hepatitis C who
were non-responders to a previous treatment.
J Hepatol 1999;31:1–7.
93. Scotto G, Fazio V, Tantimonaco G. Pilot study of a
short course of ribavirin and alpha-interferon in
the treatment of chronic active hepatitis C not
responding to alpha-interferon alone. Ital J
Gastroenterol 1996;28:505–11.
94. Sostegni R, Ghisetti V, Pittaluga F, Marchiaro G,
Rocca G, Borghesio E, et al. Sequential versus
concomitant administration of ribavirin and
interferon alfa-n3 in patients with chronic hepatitis
C not responding to interferon alone: results of a
randomized, controlled trial. Hepatology 1998;
28:341–6.
95. Toccaceli F, Grimaldi M, Rosati S, Palazzini E,
Laghi V. Ribavirin plus human leucocyte
interferon alpha for the treatment of interferon
resistant chronic hepatitis C: a controlled trial.
Hepatol Res 1997;8:106–12.
96. Barbaro G, Di Lorenzo G, Belloni G, Ferrari L,
Paiano A, Del Poggio P, et al. Interferon alpha-2B
and ribavirin in combination for patients with
chronic hepatitis C who failed to respond to, or
relapsed after, interferon alpha therapy: a
randomized trial. Am J Med 1999;107:112–18.
97. Bell H, Hellum K, Harthug S, Myrvang B,
Ritland S, Maeland A, et al. Treatment with
interferon-alpha2a alone or interferon-alpha2a
plus ribavirin in patients with chronic hepatitis C
previously treated with interferon-alpha2a. Scand J
Gastroenterol 1999;34:194–8.
98. Bellobuono A, Mondazzi L, Tempini S, Silini E,
Vicari F, Ideo G. Ribavirin and interferon-alpha
combination therapy vs interferon-alpha alone in
the retreatment of chronic hepatitis C: a
randomized clinical trial. J Viral Hepat 1997;
4:185–91.
99. Brillanti S, Miglioli M, Barbara L. Combination
antiviral therapy with ribavirin and interferon alfa
in interferon alfa relapsers and non-responders:
Italian experience. J Hepatol 1995;23:13–15.
100. Milella M, Santantonio T, Pietromateria G, Maselli
R, Casalino C, Mariano N, et al. Retreatment of
non-responder or relapser chronic hepatitis C
patients with interferon plus ribavirin vs interferon
alone. Ital J Gastroenterol Hepatol 1999;31:211–15.
101. Salmeron J, Ruiz E, Torres C, Rodriguez R,
Lavin I, Quintero D, et al. Interferon versus
ribavirin plus interferon in chronic hepatitis C
previously resistant to interferon: a randomized
trial. Liver 1999;19:275–80.
102. Bresci G, Parisi G, Bertoni M, Capria A. Highdose
interferon plus ribavirin in chronic hepatitis
C not responding to recombinant alphainterferon.
Dig Liver Dis 2000;32:703–7.
103. Ferenci P, Stauber R, Steindl-Munda P,
Gschwantler M, Fickert P, Datz C, et al. Treatment
of patients with chronic hepatitis C not responding
to interferon with high-dose interferon alpha with
or without ribavirin: final results of a prospective
randomized trial. Eur J Gastroenterol Hepatol
2001;13:699–705.
104. Tripi S, DiGaetano G, Soresi M, Cartabellotta F,
Vassallo R, Carroccio A. Interferon-alpha alone
versus interferon-alpha plus ribavirin in patients
with chronic hepatitis C not responding to
previous interferon-alpha treatment. Biodrugs
2000;13:299–304.
105. Cavalletto L, Chemello L, Donada C, Casarin P,
Belussi F, Bernardinello E, et al. The pattern of
response to interferon alpha (alpha-IFN) predicts
sustained response to a 6-month alpha-IFN and
ribavirin retreatment for chronic hepatitis C.
TVVH Study Group. J Hepatol 2000;
33:128–34.
106. Andreone P, Cursaro C, Gramenzi A, Fiorino S,
di Giammarino L, Miniero R, et al. Interferon
alpha plus ketoprofen or interferon alpha plus
ribavirin in chronic hepatitis C non-responder to
interferon alpha alone: results of a pilot study.
Ital J Gastroenterol Hepatol 1999;31:688–94.
107. Brillanti S, Garson J, Foli M, Whitby K, Deaville R,
Masci C, et al. A pilot study of combination
therapy with ribavirin plus interferon alfa for
interferon alfa-resistant chronic hepatitis C.
Gastroenterology 1994;107:812–17.
108. De Ledinghen V, Trimoulet P, Winnock M,
Bernard PH, Bourliere M, Portal I, et al. Daily or
three times per week interferon alpha-2b in
combination with ribavirin or interferon alone for
the treatment of patients with chronic hepatitis C
not responding to previous interferon alone.
J Hepatol 2002;36:819–26.
109. Malik AH, Kumar KS, Malet PF, Ostapowicz G,
Adams G, Wood M, et al. A randomized trial of
high-dose interferon alpha-2b, with or without
ribavirin, in chronic hepatitis C patients who have
not responded to standard dose interferon. Aliment
Pharmacol Ther 2002;16:381–8.
110. Gaeta GB, Stornaiuolo G, Stanzione M, Ascione T,
Pasquazzi C, Taliani G, et al. Interferon-alpha plus
amantadine in chronic hepatitis C resistant to
interferon alone: a pilot randomized study. J Viral
Hepat 2001;8:284–6.
111. Bacosi M, Russo F, D’innocenzo S, Santolamazza
M, Miglioresi L, Ursitti A, et al. Amantadine and
interferon in the combined treatment of hepatitis
C virus in elderly patients. Hepatol Res 2002;
22:231–9.
112. Teuber G, Berg T, Naumann U, Raedle J,
Brinkmann S, Hopf U, et al. Randomized,
placebo-controlled, double-blind trial with
interferon-alpha with and without amantadine
sulphate in primary interferon-alpha
nonresponders with chronic hepatitis C. J Viral
Hepat 2001;8:276–83.
113. Teuber G, Berg T, Lafrenz M, Weidenbach H,
Schoelmerich J, Wietzke-Braun P, et al.
Randomized, controlled trial with interferon-alpha
(IFN-alpha) combined with ribavirin with and
without amantadine sulfate in primary IFN-alpha
nonresponsive patients with chronic hepatitis C.
J Hepatol 2001;34:23.
114. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L.
Triple antiviral therapy as a new option for
patients with interferon nonresponsive chronic
hepatitis C. Hepatology 2000;32:630–4.
115. Shiffman ML, Hofmann CM, Gabbay J, Luketic
VA, Sterling RK, Sanyal AJ, et al. Treatment of
chronic hepatitis C in patients who failed
interferon monotherapy: effects of higher doses of
interferon and ribavirin combination therapy. Am J
Gastroenterol 2000;95:2928–35.
116. Makris M, Baglin T, Dusheiko G, Giangrande PL,
Lee CA, Ludlam CA, et al. Guidelines on the
diagnosis, management and prevention of
hepatitis in haemophilia. Haemophilia 2001;
7:339–45.
117. Fontana RJ, Lok ASF. Noninvasive monitoring of
patients with chronic hepatitis C. Hepatology
2002;36:S57–64.
118. Herve S, Savoye G, Riachi G, Hellot MF, Goria O,
Lerebours E, et al. Chronic hepatitis C with normal
or abnormal aminotransferase levels: is it the same
entity? Eur J Gastroenterol Hepatol 2001;13:495–500.
119. Albloushi SS, Murray FE, Callagy G, Courtney MG,
O’Keane JC, Kay E. Changes in liver
histopathology in women infected with hepatitis C
through contaminated anti-D immunoglobulin
injections in Ireland. Eur J Gastroenterol Hepatol
1998;10:69–73.
120. Forns X, Ampurdanes S, Llovet JM, Aponte J,
Quinto L, Martinez-Bauer E, et al. Identification of
chronic hepatitis C patients without hepatic
fibrosis by a simple predictive model. Hepatology
2002;36:986–92.
121. Dienstag JL. The role of liver biopsy in chronic
hepatitis C. Hepatology 2002;36:S152–60.
122. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-
Sieberer U, Kurth BM, et al. Cost-effectiveness of
peginterferon 2 b plus ribavirin versus interferon 2b
plus ribavirin for initial treatment of chronic
hepatitis C. Gut 2003;52:425–32.
123. Alberti A, Boccato S, Vario A, Benvegnu L.
Therapy of acute hepatitis C. Hepatology 2002;
36:S195–200.
124. Patel R, Germer JJ, Tocci G, Visco-Comandini U,
Antonucci G, Muir AJ, et al. Treatment of acute
hepatitis C with interferon alfa-2b [1](multiple
letters). N Engl J Med 2002;346:1091–2.
125. Patel R, Germer JJ, Tocci G, Visco-Comandini U,
Antonucci G, Muir AJ, et al. Treatment of acute
hepatitis C with interferon alfa-2b [1](multiple
letters). N Engl J Med 2002;346:1091–2.
126. Bennett WG, Inoue Y, Beck JR, Wong JB,
Pauker SG, Davis GL. Estimates of the costeffectiveness
of a single course of interferon-alpha
2b in patients with histologically mild chronic
hepatitis C. Ann Intern Med 1997;127:855–65.
127. Stein K, Rosenberg W, Wong J. Cost effectiveness
of combination therapy for hepatitis C: a decision
analytic model. Gut 2002;50:253–8.
128. Wong JB, Bennett WG, Koff RS, Pauker SG.
Pretreatment evaluation of chronic hepatitis C:
risks, benefits, and costs. JAMA 1998;280:2088–93.
129. Younossi ZM, Singer ME, McHutchison JG,
Shermock KM. Cost effectiveness of interferon
alpha 2b combined with ribavirin for the
treatment of chronic hepatitis C. Hepatology
1999;30:1318–24.
130. Buti M, Medina M, Casado MA, Wong JB,
Fosbrook L, Esteban R. A cost-effectiveness analysis
of peginterferon alfa-2b plus ribavirin for the
treatment of naive patients with chronic hepatitis
C. Aliment Pharmacol Ther 2003;17:687–94.
131. Wong JB, Nevens F. Cost-effectiveness of
peginterferon alfa-2b plus ribavirin compared to
interferon alfa-2b plus ribavirin as initial treatment
of chronic hepatitis C in Belgium. Acta Gastroenterol
Belg 2002;65:110–11.
132. Wong JB, McHutchison JG, Manns MP,
Albrecht JK. Economic and clinical implications of
the loss of adherence to weight-based dosing of
ribavirin and peginterferon alfa-2b for chronic
hepatitis C. Boston, MA: American Association for
the Study of Liver Diseases; 2002.
133. Wong JB, Rosenber WM, Manns MP,
McHutchison JG, Davis GL, Albrecht JK. Is
peginterfon alfa-2b plus ribavirin cost-effective for
treating chronic hepatitis C in the United
Kingdom? Geneva: European Association for the
Study of the Liver; 2003.
134. Gish R, Bzowej N, Brooks L. Treatment with
pegylated interferon alfa-2b in combination with
ribavirin improved health-related quality of life
compared with interferon alfa-2b plus ribavirin in
chronic hepatitis C. Alexandra, VA: American
Association for the Study of Liver Diseases; 2002.
135. Hassanein TI, Cooksley G, Sulkowski M, Smith C,
Marinos G, Lai MY, et al. Treatment with 40 kDa
peginterferon alfa-2a (Pegasys®) in combination
with ribavirin significantly enhances quality of life
compared with interferon alfa-2b plus ribavirin
[abstract]. Hepatology 2001;34:243A.
136. Hassanein TI, Cooksley GE, Sulkowski M,
Smith C, Marinos G, Lai M-Y, et al. QoL benefits
observed as early as week 2 with peginterferon
alfa-2a (40kD) (Pegasys) in combination with
ribavirin (RBV) versus interferon alfa-2b plus RBV.
European Association for the Study of the Liver,
37th Annual Meeting, Madrid, 15–21 April 2002.
137. Bernstein D, Kleinman L, Barker CM, Revicki DA,
Green J. Relationship of health-related quality of
life to treatment adherence and sustained response
in chronic hepatitis C patients. Hepatology 2002;
35:704–8.
138. Rasenack J, Zeuzem S, Feinman S, Heathcote E,
Manns M, Yoshida E, et al. Peginterferon alpha-2a
(40kD) [Pegasys®] Improves HR-QoL outcomes
compared with unmodified interferon alpha-2a
[Roferon®-A] In patients with chronic hepatitis C.
Pharmacoeconomics 2003;21:341–9.
139. Feagan BG, Trepo C, Lindsay KL, Niederau C,
Wong CJ, Weng CSW, et al. The impact of
pegylated interferon alfa-2b on health-related
quality of life in chronic hepatitis C patients.
Hepatology 2000;32:590.
140. National Centre for Clinical Excellence. Guidance for
manufacturers and sponsors. Technology Appraisals
Process Series No. 5. London: NICE; 2002.
141. Drummond MF, O’Brien BJ, Stoddart G, Torrance
GW. Methods for the economic evaluation of health care
programmes, 2nd ed. New York: Oxford University
Press; 1997.
142. Gold M. Cost-effectiveness in health and medicine.
Oxford: Oxford University Press; 1996.
143. Kim WR, Poterucha JJ, Hermans JE, Therneau
TM, Dickson ER, Evans RW, et al. Costeffectiveness
of 6 and 12 months of interferonalpha
therapy for chronic hepatitis C. Ann Intern
Med 1997;127:866–74.
144. Wong JB. Interferon treatment for chronic
hepatitis B or C infection: costs and effectiveness.
Acta Gastroenterol Belg 1998;61:238–42.
145. Wong JB. Estimating the cost-effectiveness of
ribavirin and pegylated interferon alfa-2B for
chronic hepatitis C. Hepatology 2000;32:1062.
146. Wong JB, Koff RS. Watchful waiting with periodic
liver biopsy versus immediate empirical therapy
for histologically mild chronic hepatitis C. A costeffectiveness
analysis. Ann Intern Med
2000;133:665–75.
147. Stein K, Jenkins B, Dalziel K, Horne J, Walker A,
Royle P, et al. Screening for hepatitis C among
injecting drug users and in genitourinary medicine
clinics: systematic reviews of effectiveness,
modelling study and national survey of current
practice. Health Technol Assess 2002;6(31).
148. Department of Health. Hepatitis C strategy for
England. London: Department of Health; 2002.
149. Seeff, L. Natural history of hepatitis C. Hepatology
1997;26(3), 21–8S.
150. Crowe J, Doyle C, Fielding JF. Presentation of
hepatitis C in a unique uniform cohort 17 years
from inoculation [abstract]. Gastroenterology
1995;108:1054A.
151. Power JP, Lawlor E, Davidson F, Yap PL,
Kenny WE, Whelton MJ, et al. Hepatitis C
viraemia in recipients of Irish intravenous anti-D
immunoglobulin. Lancet 1994;344:1166–7.
152. Darby SC, Ewart DW, Giangrande PL, Spooner RJ,
Rizza CR, Dusheiko GM, et al. Mortality from liver
cancer and liver disease in haemophilic men and
boys in UK given blood products contaminated
with hepatitis C. UK Haemophilia Centre
Directors’ Organisation. Lancet 1997;350:1425–31.
153. Regan F, Hewitt P, Contreras BJ, on behalf of the
TTI Study Group. Prospective investigation of
transfusion transmitted infection in recipients of
over 20,000 units of blood. BMJ 2000;320:403–7.
154. Harris HE, Ramsay ME, Heptonstall J, Soldan K,
Eldridge KP. The HCV National Register: towards
informing the natural history of hepatitis C
infection in the UK. J Viral Hepat 2000;7:420–7.
155. Alter HJ, Conry CC, Melpolder J, Tan D,
Van Raden M, Herion D, et al. Hepatitis C in
asymptomatic blood donors. Hepatology 1997;
26:29–33S.
156. Freeman AJ, Dore GJ, Law MG, Thorpe M,
Von Overbeck J, Lloyd AR, et al. Estimating
progression to cirrhosis in chronic hepatitis C virus
infection. Hepatology 2001;34:809–16.
157. Fattovich G, Giustina G, Degos F, Tremolada F,
Diodati G, Almasio P, et al. Morbidity and
mortality in compensated cirrhosis type C:
a retrospective follow-up study of 384 patients.
Gastroenterology 1997;112:463–72.
158. Di Bisceglie AM. Hepatitis C and hepatocellular
carcinoma. Hepatology 1997;26:34–8S.
159. Dienstag JL. The natural history of chronic
hepatitis C and what we should do about it.
Gastroenterology 1997;112:651–5.
160. Hoofnagle JH. Hepatitis C: the clinical spectrum
of disease. Hepatology 1997;26:15–20S.
161. Afdhal N, Flamm S, Imperial J, Malet PF, Tong M,
Campagna J, et al. Pegylated (40 kDa) interferon
alfa-2a (Pegasys®) in combination with ribavirin,
mycophenolate mofetil (CellCept®), amantadine,
or amantadine plus ribavirin in patients that did
not respond to Rebetron® therapy: a preliminary report of a randomized, multicenter study
[abstract]. Gastroenterology 2001;120:1963.
162. Herrine SK, Brown R, Jr, Esposito S, Lok A,
Galati JS, Bernstein DE, et al. Pegylated (40 kDa)
interferon alfa-2a (Pegasys®) in combination with
ribavirin, mycophenolate mofetil (CellCept®),
amantadine, or amantadine plus ribavirin in
patients that relapsed on Rebetron™ therapy: a
preliminary report of a randomized, multicenter
efficacy and safety study [abstract]. Gastroenterology
2001;120:A-384.
163. Di Bisceglie A-M, Bernstein, DE, Rustgi V.-R,
Gitlin N, Jeffers LJ, Simon D. Pegylated (40 kDa)
interferon alfa-2A (Pegasys®) in new combination
therapies: a report of a randomized, multicenter
efficacy and safety study [abstract]. J Hepatol
2001;34:143.
164. Lawitz EJ, Cantu NS, Adams F, Davis M,
Sperling R, Fein S, et al. Triple therapy compared
to standard pegylated interferon alfa 2b plus
weight based ribavirin for treatment naive patients
with chronic hepatitis C: 24 week viral clearance
[TRI-STAR trial] [abstract]. Gastroenterology
2002;123:74.
165. Zeuzem S, Herrmann E, Lee JH, Marinos G,
Modi M, Roth WK. Effect of ribavirin on viral
kinetics in hepatitis C virus genotype 1 infected
patients treated with pegylated interferon alpha 2a
[abstract]. Hepatology 2001;34:1544.
166. Lindsay KL, McHutchison JG, Ling MH,
Albrecht JK. Response to PEG-IFN alpha2b
(PEG-Intron) in Blacks and Hispanics with HCV is
higher than with standard IFN alpha2b (IFN)
[abstract]. Hepatology 2000;32:347A.
167. Wong JB, Siebert U, Manns MP, McHutchison JG,
Sroczynski G, Wasem J, et al. Cost-effectiveness of
ribavirin and pegylated interferon alfa-2b for
initial treatment of chronic hepatitis C [abstract].
Hepatology 2001;34:2075.
168. Buti M, Casado MA, Medina M, Fosbrook L,
Esteban R. Is Peg-interferon plus Ribavirin a costeffective
therapy, and if so, what is the most
efficient way to use this therapy in naive patients
with chronic hepatitis C? [abstract]. J Hepatol
2002;36:357.
169. Siebert U, Sroczynski G, Rossol S, Wasem J,
Ravens-Sieberer U, Kurth BM, et al. Costeffectiveness
of peginterferon alpha-2b plus
ribavirin compared with interferon alpha-2b plus
ribavirin for initial treatment of chronic hepatitis
C [abstract]. J Hepatol 2002;36:463.
170. Shiffman M, Pockros PJ, Reddy RK, Wright TL,
Reindollar R, Fried MW, et al. A controlled,
randomized, multicenter, descending dose phase
II trial of pegylated interferon alfa-2a (PEG) vs
standard interferon alfa-2a (IFN) for treatment of
chronic hepatitis C [abstract]. Gastroenterology
1999;116:A1275.
171. Neumann AU, Zeuzem S, Brunda MJ,
Hoffman JH. Rapid viral response to treatment
with pegylated (40kDa) interferon ALFA-2A
(Pegasys™) is strongly predictive of a sustained
virologic response in patients with chronic
hepatitis C (CHC) [abstract]. Hepatology 2000;
32:633.
172. Pockros PJ, Heathcote EJ, Shiffman ML, Bain VG,
Zeuzem S, Rustgi VR, et al. Efficacy of pegylated
(40kDa) interferon alfa-2A (Pegasys™) in
randomized trials of patients with chronic hepatitis
C with and without cirrhosis: correlation of
virologic responses with baseline liver histology
and genotype [abstract]. Hepatology 2000;32:1131.
173. Sherman M, Dusheiko GM, Haeussinger D,
Marinos G, Munoz-Espinoza L, Salmeron J, et al.
Superior virologic response in genotype 4 chronic
hepatitis C patients treated with pegylated (40kDa)
interferon alfa-2A (Pegasys™) compared with
standard interferon [abstract]. Hepatology 2000;
32:754.
174. Shiffman ML, Fromm H, Mills P, Moonka DK,
Fried MW, Berg C, et al. Enhanced efficacy of
pegylated (40kDa) interferon alfa-2A (Pegasys™)
compared with interferon alfa-2A (Roferon-A™)
for chronic hepatitis C in Blacks [abstract].
Hepatology 2000;32:753.
175. Zeuzem S, Heathcote EJ, Shiffman ML, Wright
TL, Bain VG, Sherman M, et al. Twelve weeks of
follow-up is sufficient for the determination of
sustained virologic response in patients with
chronic hepatitis C treated with pegylated
(40 kDa) interferon alfa-2a (Pegasys™) and
interferon alfa-2a (Roferon-A®). Hepatology
2000;32:785.
176. Cooksley G, Foster G, Green J, Kleinman L,
Hakim Z, Revicki D. The effect of successful antiviral
therapy on health-related quality of life for
patients with chronic hepatitis C and cirrhosis.
Gastroenterology 2000;118. Dallas, TX: American
Association for the Study of Liver Diseases.
177. Kamal SM, Peter T, Rasenack JW. PEG (40kDa)
interferon alpha-2a therapy enhances HCV
specific CD4+ T helper 1 responses during and
after treatment [abstract]. Gastroenterology 2001;
120:A-55.
178. Heathcote EJ, Balart LA, Shiffman ML,
Pockros PJ, Lee SS, Reddy KR, et al. Pegylated
(40kDa) interferon alfa-2a (Pegasys™) is superior
to interferon alfa-2a (Roferon-A®) in improving
posttreatment histologic outcome in chronic
hepatitis C patients 1584 [abstract]. Hepatology
2000;32:246.